Gram Research analysis shows that bacteria exposed to trimethoprim-sulfamethoxazole antibiotics all independently evolved the same genetic mutation in a protein called dihydrofolate reductase. This I99L mutation reduced antibiotic effectiveness by 4 to 16 times by preventing the drug from attaching to its target, while the protein continued functioning normally. The same mutation has been found in real patient samples, suggesting this is how resistance actually develops in nature.
Scientists discovered how bacteria develop resistance to trimethoprim-sulfamethoxazole, an important antibiotic used to treat serious infections. By watching bacteria evolve in the lab under increasing antibiotic pressure, researchers found that all bacteria eventually developed the same genetic mutation in a protein called dihydrofolate reductase. This mutation makes the antibiotic less effective by preventing it from binding to its target. Understanding this resistance mechanism could help doctors develop better treatments and preserve the effectiveness of this crucial medication for patients who need it most.
Key Statistics
A 2026 laboratory evolution study published in ACS Infectious Diseases found that all bacterial populations independently developed an identical I99L mutation in dihydrofolate reductase when exposed to increasing trimethoprim-sulfamethoxazole concentrations.
The I99L mutation in dihydrofolate reductase increased bacterial resistance to trimethoprim by 4 to 16 times according to allelic reconstruction experiments, while preserving the protein’s normal catalytic function.
Researchers identified that early antibiotic resistance involved multiple different genetic mutations across efflux pump and folate metabolism genes, but all evolutionary pathways converged on the single I99L mutation at high antibiotic concentrations.
The Quick Take
- What they studied: How bacteria develop resistance to trimethoprim-sulfamethoxazole (a common antibiotic combination) when exposed to increasing doses over time
- Who participated: Laboratory populations of Burkholderia thailandensis bacteria, a safe cousin of a dangerous species that causes serious infections in humans
- Key finding: All bacterial populations independently evolved the same genetic mutation (I99L) in a protein called dihydrofolate reductase, which reduced antibiotic effectiveness by 4 to 16 times
- What it means for you: This research helps scientists understand how dangerous bacteria become resistant to antibiotics, which could lead to better treatments. However, this is basic laboratory research and does not directly change how doctors prescribe antibiotics today
The Research Details
Researchers took harmless bacteria and exposed them to gradually increasing concentrations of trimethoprim-sulfamethoxazole in the laboratory. They repeated this process over many generations, watching how the bacteria adapted and survived. At each stage, they used genetic sequencing to identify which genes changed and which mutations appeared most frequently.
The scientists then took the most common mutation they found and tested it in isolation to confirm it actually caused antibiotic resistance. They also studied the three-dimensional structure of the mutated protein to understand exactly how it stopped the antibiotic from working. This combination of evolutionary observation, genetic analysis, and biochemical testing provided strong evidence for their conclusions.
This approach mimics what happens in real infections, where bacteria face constant pressure from antibiotics and must adapt to survive. By understanding the specific genetic changes bacteria make, scientists can predict which mutations are most likely to emerge in patients and develop strategies to prevent or overcome them. The fact that all bacterial populations independently arrived at the same mutation suggests this is a particularly effective resistance strategy.
The study used whole-genome sequencing, which provides complete genetic information rather than guessing. The researchers confirmed their findings through multiple methods: evolutionary observation, genetic reconstruction, and biochemical analysis. They used a safe bacterial species as a model, which allowed them to conduct experiments that would be too dangerous with the actual disease-causing bacteria. The convergence on a single mutation across multiple independent populations strengthens confidence in the results.
What the Results Show
When bacteria were exposed to increasing antibiotic concentrations, they initially developed diverse mutations in multiple genes related to antibiotic resistance. Early adaptations involved changes in genes controlling efflux pumps (proteins that pump antibiotics out of cells) and genes involved in folate metabolism. However, as antibiotic pressure increased, a remarkable pattern emerged: all bacterial populations independently developed the same single mutation, called I99L, in the dihydrofolate reductase protein.
This I99L mutation became the dominant change in all populations at high antibiotic concentrations. When researchers tested this mutation in isolation, it increased bacterial resistance by 4 to 16 times, meaning bacteria with this mutation could survive in much higher antibiotic concentrations than normal bacteria. The mutation works by changing the shape of the protein slightly, which prevents the antibiotic trimethoprim from attaching to it effectively, even though the protein can still perform its normal job.
Early in the evolution process, bacteria used multiple different resistance strategies simultaneously, including pumping antibiotics out of cells and altering folate metabolism. However, these early adaptations were less effective than the I99L mutation. The research also showed that this same I99L mutation has been found in real bacterial samples taken from patients with chronic infections, suggesting the laboratory findings reflect what actually happens in nature.
Previous research identified that bacteria can resist this antibiotic through various mechanisms, but the specific genetic basis in Burkholderia pseudomallei (the disease-causing species) was not well understood. This study provides the clearest evidence yet that dihydrofolate reductase is the primary target for resistance evolution. The finding that the same mutation appears in both laboratory evolution and patient samples validates this laboratory model as a reliable way to study real-world resistance.
This research used a laboratory-safe bacterial species rather than the actual disease-causing bacteria, so some differences may exist in real infections. The study examined evolution in controlled laboratory conditions with pure bacterial populations, which is simpler than the complex environment inside a human body where multiple bacterial strains and immune responses interact. The research does not address how quickly this resistance develops in actual patients or how common this mutation is in clinical samples worldwide.
The Bottom Line
This research is foundational science that helps scientists understand antibiotic resistance mechanisms. It does not provide direct recommendations for patients or doctors at this time. However, it supports the importance of using antibiotics appropriately and completing full courses as prescribed to minimize the development of resistance. Healthcare providers should continue monitoring for resistance patterns and consider this research when developing new treatment strategies.
Infectious disease specialists, microbiologists, and pharmaceutical researchers should pay attention to this work as it identifies a key resistance mechanism. Patients with melioidosis (the infection this antibiotic treats) should understand that resistance is a real concern, making appropriate antibiotic use critical. Public health officials tracking antibiotic resistance patterns should monitor for this specific mutation in clinical samples.
This is basic research that may take 5 to 10 years to translate into clinical applications. Understanding the resistance mechanism is the first step toward developing new antibiotics or combination therapies that could overcome this resistance.
Frequently Asked Questions
How do bacteria become resistant to antibiotics like trimethoprim-sulfamethoxazole?
Bacteria develop resistance through genetic mutations that change proteins targeted by antibiotics. This study found that under antibiotic pressure, bacteria independently evolved the same I99L mutation in dihydrofolate reductase, which prevents the antibiotic from binding while preserving the protein’s normal function.
Can the same antibiotic resistance mutation appear in different bacteria?
Yes. This research demonstrated that multiple independent bacterial populations all developed the identical I99L mutation when facing the same antibiotic pressure, suggesting certain mutations are particularly effective resistance strategies that evolution repeatedly discovers.
Does this research mean trimethoprim-sulfamethoxazole will stop working soon?
This laboratory research identifies how resistance can develop, but it does not predict clinical timelines. Resistance development depends on many factors including antibiotic use patterns, patient compliance, and infection severity. Appropriate antibiotic use remains important.
Why do scientists study bacteria in the lab instead of just looking at patient samples?
Laboratory evolution allows scientists to watch resistance develop in real-time and identify the specific genetic changes responsible. This controlled approach reveals mechanisms that might be hidden among complex patient data, providing insights to guide clinical research.
Could this mutation affect how the antibiotic works in human bodies?
The mutation was identified in bacteria from patient samples, suggesting it functions similarly in real infections. However, laboratory conditions differ from the human body, so additional research is needed to fully understand clinical implications.
Want to Apply This Research?
- Users could track antibiotic prescriptions received and note any treatment failures or extended infection durations, helping identify patterns in their personal health history
- Set reminders to complete full antibiotic courses as prescribed, even when feeling better, to reduce the likelihood of resistance development
- Log infection episodes and their outcomes over time to identify personal patterns and share with healthcare providers during appointments
This research describes laboratory findings about how bacteria develop antibiotic resistance and does not provide medical advice. Patients should not change antibiotic use based on this study. Always follow your doctor’s prescriptions and complete full antibiotic courses as directed. If you have concerns about antibiotic resistance or treatment effectiveness, discuss them with your healthcare provider. This research is foundational science that may take years to translate into clinical applications.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.